Aptar Pharma has announced the appointment of Jean-Marc Pardonge as President of Aptar Pharma’s Prescription Division, succeeding Salim Haffar, and as General Manager of Aptar Stelmi. Aptar's prescription division develops and manufactures a range of nasal and pulmonary delivery devices. Pardonge has worked in the prescription division since 2000, first as R&D … [Read more...] about Aptar Pharma appoints Jean-Marc Pardonge President of prescription division
People
NanoBio promotes David Peralta to CEO
NanoBio Corporation, which is developing a several intranasal vaccines, has announced that David Peralta will succeed James R. Baker as the company's Chief Executive Officer after Baker was hired by Merck as Senior VP, Head Global Vaccine Franchise. In 2011, NanoBio announced a collaboration with Merck on an intranasal RSV vaccine. Peralta has worked for NanoBio since … [Read more...] about NanoBio promotes David Peralta to CEO
Freeman Technology expands Asian business
Powder characterization specialist Freeman Technology has reached an agreement with distribution partner DKSH to expand into China. DKSH already distributes Freeman's FT4 Powder Rheometer in Singapore, Malaysia, Thailand and Taiwan and will now distribute the universal powder tester from DKSH China headquarters in Shanghai and other locations in China. Freeman … [Read more...] about Freeman Technology expands Asian business
Lightlake appoints former FDA commissioner as advisor
Lightlake Therapeutics, which is developing naloxone nasal sprays for several eating disorders, has announced the appointment of former FDA Commissioner David Kessler as a strategic advisor. Kessler is the author of The End of Overeating: Taking Control of the Insatiable American Appetite. Lightlake CEO Roger Crystal commented, "We are very pleased to add Dr. … [Read more...] about Lightlake appoints former FDA commissioner as advisor
Melbourn Scientific adds dedicated GMP nasal spray laboratory
In order to meet rising demand for its GMP nasal spray testing services, Melbourn Scientific has dedicated a laboratory to analysis of droplet size, particle characterization, spray pattern, plume geometry, and device performance testing. The company has also appointed Liz Parkhouse as business development executive for the nasal spray testing service. According … [Read more...] about Melbourn Scientific adds dedicated GMP nasal spray laboratory
Proveris expands UK operations, promotes Ivan Prince
OINDP testing specialist Proveris Scientific UK Limited, a wholly owned subsidiary of Proveris Scientific Corporation, is expanding its operations to support increasing business in Asia and Europe. In addition to hiring a new field service engineer specifically for those regions, the company plans to have a new training center at the Chichester headquarters completed … [Read more...] about Proveris expands UK operations, promotes Ivan Prince
Mucosis appoints Thomas Johnston as CEO
Dutch biotech company Mucosis B.V. has promoted Thomas Johnston, the company's Chief Business Officer since May 2011, as CEO, replacing Govert Schouten. Prior to joining Mucosis, which is developing intranasal vaccines based on its Mimopath platform, Johnston was VP of Strategy at Novavax. Mucosis Chairman of the Board John Lambert said, "Tom has more than 15 years … [Read more...] about Mucosis appoints Thomas Johnston as CEO
New CEO for Insmed
Arikace developer Insmed Incorporated has appointed Will Lewis, co-founder of Aegerion Pharmaceuticals, to succeed Tim Whitten as President and Chief Executive Officer. According to the company, Whitten has resigned from the board of directors as well, and Lewis will join the board. Donald J. Hayden, Jr., who was appointed Executive Chairman earlier this year, … [Read more...] about New CEO for Insmed
Civitas Therapeutics appoints Bryan Stuart as Chief Business Officer
Civitas Therapeutics has appointed Bryan Stuart as Chief Business Officer. Civitas, which was spun off from Alkermes, is developing carrier-free inhaled drugs based on its ARCUS particle engineering platform and inhaler. The company's lead candidate is CVT-301 inhaled L-dopa for the treatment of Parkinson's disease. Civitas CEO Glenn Batchelder said, “We are very … [Read more...] about Civitas Therapeutics appoints Bryan Stuart as Chief Business Officer
Pulmatrix appoints Robert Clarke as CEO
Pulmatrix has announced that Robert Clarke will succeed Robert Connelly as the company's Chief Executive Officer. Clarke has been with the company, which is developing inhaled drugs based on its proprietary iSPERSE (inhaled small particles easily respirable and emitted) platform, since 2004 as VP of Research & Development and as Chief Scientific Officer. Clarke … [Read more...] about Pulmatrix appoints Robert Clarke as CEO